Want to see CYPH full AI Analyst Report?
CYPH Stock Chart & Stats
$0.70
<$0.01(0.29%)
―
--
Day’s Range― - ―
52-Week Range$0.23 - $3.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.57M
Market Cap
$74.53M
Enterprise Value$36.52M
Total Cash (Recent Filing)$6.69M
Total Debt (Recent Filing)$38.00K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 17, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding106,464,485
10 Day Avg. Volume1,752,086
30 Day Avg. Volume5,569,896
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company’s extremely low reported debt provides durable financial flexibility: it reduces interest and covenant risk, preserves borrowing capacity, and gives management optionality for future capital raises or strategic investments without immediate balance-sheet strain. This matters over months as a buffer against cash burn and for executing long-term plans.
Shareholder SupportInvestor approval of directors and advisory pay signals continuity and legitimacy for governance choices. Sustained shareholder backing lowers the chance of disruptive proxy fights, supports management’s multi‑year strategy execution, and stabilizes oversight—important for longer‑term planning and capital‑raising credibility.
Audit OversightRatification of a recognized independent auditor strengthens financial reporting credibility and audit continuity. Reliable external audit oversight supports regulatory compliance, investor confidence, and smoother fundraising or M&A processes over time, reducing execution friction tied to financial disclosures.
Bears Say
Severe Cash BurnPersistent, large negative operating and free cash flow is a structural weakness: the business is not self‑funding and will likely need repeated external financing. Over months this raises dilution risk, constrains R&D or go‑to‑market spending, and limits the company’s ability to pursue strategic initiatives without securing new capital.
Minimal Revenue TractionNear‑zero trailing revenue versus very large losses indicates weak product‑market fit or stalled commercialization. Structurally, without meaningful recurring revenue, fixed costs and R&D burdens remain unsustainable, making profitability and margin recovery unlikely without a clear, durable revenue inflection.
Equity ErosionSharp decline in shareholders’ equity reflects cumulative losses and value erosion, reducing the balance‑sheet buffer for shocks. Over 2–6 months this limits strategic optionality, undermines investor confidence, and can increase cost of capital or force dilutive financing if operations continue to burn cash.
Cypherpunk Technologies News
CYPH FAQ
What was Cypherpunk Technologies Inc.’s price range in the past 12 months?
Cypherpunk Technologies Inc. lowest stock price was $0.23 and its highest was $3.70 in the past 12 months.
What is Cypherpunk Technologies Inc.’s market cap?
Cypherpunk Technologies Inc.’s market cap is $74.53M.
When is Cypherpunk Technologies Inc.’s upcoming earnings report date?
Cypherpunk Technologies Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 36 days.
How were Cypherpunk Technologies Inc.’s earnings last quarter?
Cypherpunk Technologies Inc. released its earnings results on May 14, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.46.
Is Cypherpunk Technologies Inc. overvalued?
According to Wall Street analysts Cypherpunk Technologies Inc.’s price is currently Undervalued.
Does Cypherpunk Technologies Inc. pay dividends?
Cypherpunk Technologies Inc. does not currently pay dividends.
What is Cypherpunk Technologies Inc.’s EPS estimate?
Cypherpunk Technologies Inc.’s EPS estimate is -0.03.
How many shares outstanding does Cypherpunk Technologies Inc. have?
Cypherpunk Technologies Inc. has 106,464,485 shares outstanding.
What happened to Cypherpunk Technologies Inc.’s price movement after its last earnings report?
Cypherpunk Technologies Inc. reported an EPS of -$0.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Cypherpunk Technologies Inc.?
Currently, no hedge funds are holding shares in CYPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cypherpunk Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 404.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
105.88%
12-Months-Change
Fundamentals
Return on Equity
-46.86%
Trailing 12-Months
Asset Growth
150.52%
Trailing 12-Months
Company Description
Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Ownership Overview
1.63% Insiders
2.12% Mutual Funds
0.08% Other Institutional Investors
94.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---